Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01241214 · ClinicalTrials.gov registry record · Phase 2
Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
A Phase 2 study of Seasonal Allergic Rhinitis, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 579
- Enrollment target
- 7
- Study locations
NCT01241214: Completed Phase 2 study of Seasonal Allergic Rhinitis, sponsored by Idorsia Pharmaceuticals.
NCT01241214 is a Phase 2 study of Seasonal Allergic Rhinitis that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 579 participants, roughly in line with the 632-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target. The trial reports 7 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01241214, a Phase 2 study of Seasonal Allergic Rhinitis, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 579 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cetirizine
- DRUG ACT-129968
Study Locations (7)
Texas
- Clinical Investigative Site 7905 - Austin
- Clinical Investigative Site 7907 - Kerrville
- Clinical Investigative Site 7903 - New Braunfels
- Clinical Investigative Site 7901 - San Antonio
- Clinical Investigative Site 7902 - San Antonio
- Clinical Investigative Site 7904 - San Antonio
- Clinical Investigative Site 7906 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 579 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
What the finished NCT01241214 record still lists
NCT01241214 is an interventional study that assigns participants to a tested intervention. The registered 579 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 632-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target.
The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01241214 lists 7 locations in 1 state (Texas).
Frequently Asked Questions
What is clinical trial NCT01241214 about?
NCT01241214 is a clinical study titled "Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis". This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.
What is the current status of trial NCT01241214?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 579 participants. The study started on 2010-11. Estimated completion is 2011-02.
What conditions does trial NCT01241214 study?
This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.
What interventions are being tested in trial NCT01241214?
The interventions under investigation include: Placebo (DRUG), Cetirizine (DRUG), ACT-129968 (DRUG).
Who is sponsoring clinical trial NCT01241214?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01241214 being conducted?
This trial has 7 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01241214's enrollment target sits among peer trials
579 11th of 16 higher than 6 of 16 other Seasonal Allergic Rhinitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Seasonal Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
COMPLETED · Phase 2
-
Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis
COMPLETED · Phase 2
-
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects
COMPLETED · Phase 2
-
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
COMPLETED · Phase 3
-
Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05143177 · 580 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
- NCT06578104 · 580 participants
PULSED AF Post-Approval Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia